Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25352069 | 0.83 | GAA (0.69) | ALDH1A1GAALMNASMN1; SMN2KMT2A | |
| SCHEMBL2178229 | 0.78 | ALDH1A1 (0.71) | ALDH1A1LMNAPKMCA1CA2 | |
| SCHEMBL712071 | 0.77 | MEN1 (0.58) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL28047475 | 0.73 | ALDH1A1 (0.63) | ALOX12ALDH1A1GAALMNAKMT2A | |
| SCHEMBL16634495 | 0.72 | ALOX12 (1.00) | ALOX12ALDH1A1GAALMNA | |
| SCHEMBL13452528 | 0.72 | MEN1 (0.71) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9965751 | 0.71 | — | — | |
| SCHEMBL27182708 | 0.71 | ALDH1A1 (0.41) | ALOX12ALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL4200929 | 0.69 | ALDH1A1 (0.80) | ALDH1A1GAALMNASMN1; SMN2KMT2A | |
| SCHEMBL25351737 | 0.68 | GAA (0.64) | ALDH1A1GAALMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | ALOX12 1666/4885ALDH1A1 3333/4885GAA 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.